Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435084 | 0.85 | EPHX2 (0.55) | EPHX2CHRM4SMN1; SMN2FFAR4USP2 | |
| SCHEMBL17033958 | 0.78 | CHRM4 (0.57) | CHRM4LIPECHRM2 | |
| SCHEMBL2056186 | 0.76 | CHRM4 (0.55) | CHRM4CHRM2KCNH2 | |
| SCHEMBL17206997 | 0.76 | CHRM4 (0.55) | CHRM4CHRM2 | |
| SCHEMBL17025379 | 0.72 | CHRM4 (0.49) | CHRM4FFAR4LIPECHRM2KCNH2 | |
| SCHEMBL16648937 | 0.72 | POLB (0.67) | CHRM4FFAR4CHRM2POLB | |
| SCHEMBL2092977 | 0.71 | FFAR4 (0.47) | EPHX2CHRM4FFAR4CHRM2KCNH2 | |
| SCHEMBL22816541 | 0.71 | FFAR4 (0.47) | CHRM4FFAR4CHRM2KCNH2 | |
| SCHEMBL1244796 | 0.71 | FFAR4 (0.50) | CHRM4FFAR4LIPECHRM2 | |
| SCHEMBL16769747 | 0.71 | CHRM4 (0.58) | EPHX2CHRM4FFAR4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017066103-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2017-04-20 | — | — | WO | disclosed |